突变阳性晚期-话题@MedSci

#突变阳性晚期#

12篇内容 | 334人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1803601, encodeId=63ed180360147, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, objectType=article, longId=190904, objectId=3990190904f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3990190904f4, replyNumber=0, likeNumber=31, createdTime=2021-02-05, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3990190904f4, moduleTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3990190904f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, objectType=article, longId=192270, objectId=8c6d1922e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6d1922e0a7, replyNumber=0, likeNumber=34, createdTime=2020-06-06, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6d1922e0a7, moduleTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c6d1922e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803598, encodeId=3e1b180359820, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183910, objectId=6dfe18391000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dfe18391000, replyNumber=0, likeNumber=30, createdTime=2020-02-15, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dfe18391000, moduleTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dfe18391000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803603, encodeId=2bd618036036a, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=34, createdTime=2021-01-19, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803597, encodeId=53cf180359e19, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, objectType=article, longId=182628, objectId=4294182628cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4294182628cc, replyNumber=0, likeNumber=40, createdTime=2019-12-17, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4294182628cc, moduleTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4294182628cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803599, encodeId=cc4e1803599d4, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183976, objectId=367f1839e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367f1839e6b1, replyNumber=0, likeNumber=28, createdTime=2020-01-05, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367f1839e6b1, moduleTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367f1839e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803600, encodeId=bf63180360040, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=EGFR突变阳性晚期NSCLC一线治疗策略, objectType=article, longId=184327, objectId=4a2618432ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2618432ef2, replyNumber=0, likeNumber=31, createdTime=2020-10-11, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2618432ef2, moduleTitle=EGFR突变阳性晚期NSCLC一线治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2618432ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803596, encodeId=47da180359683, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略, objectType=article, longId=178512, objectId=7fb11e8512e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb11e8512e3, replyNumber=0, likeNumber=31, createdTime=2020-01-31, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb11e8512e3, moduleTitle=【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb11e8512e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803594, encodeId=9ba51803594d4, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=EGFR突变阳性晚期NSCLC的治疗方案选择, objectType=article, longId=168402, objectId=fee316840246, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee316840246, replyNumber=0, likeNumber=25, createdTime=2019-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee316840246, moduleTitle=EGFR突变阳性晚期NSCLC的治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fee316840246)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803595, encodeId=fb0718035955b, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, objectType=article, longId=168762, objectId=f104168e62dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f104168e62dd, replyNumber=0, likeNumber=26, createdTime=2019-10-20, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f104168e62dd, moduleTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f104168e62dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803593, encodeId=354a180359341, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, objectType=article, longId=124734, objectId=05dd124e34e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05dd124e34e0, replyNumber=0, likeNumber=32, createdTime=2018-07-15, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05dd124e34e0, moduleTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05dd124e34e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803592, encodeId=78811803592a8, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, objectTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, objectType=article, longId=111065, objectId=5e6c111065d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6c111065d4, replyNumber=0, likeNumber=31, createdTime=2018-06-29, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6c111065d4, moduleTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6c111065d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突变阳性晚期

2020-05-29

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局

2021-02-05

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理

2020-06-06

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**

2020-02-15

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2021-01-19

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

EGFR突变阳性晚期NSCLC的全程管理愈发重要

2019-12-17

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**

2020-01-05

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

EGFR突变阳性晚期NSCLC一线治疗策略

2020-10-11

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略

2020-01-31

智智灵药 (审核中...)

前往app查看评论内容

#突变阳性晚期#

EGFR突变阳性晚期NSCLC的治疗方案选择

2019-06-22

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择

2019-10-20

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI

2018-07-15

若水123 (审核中...)

前往app查看评论内容

#突变阳性晚期#

JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！

2018-06-29

科室
- - 订阅+
  - 更多科室
工具
服务